Related Experiment Videos
Perspective on future therapy of vasculitis.
D T Boumpas1, H D Kritikos, N G Daskalakis
1Division of Rheumatology, Clinical Immunology and Allergy, University of Crete, Medical School, P.O.Box 1393 Heraklion, Crete, Greece. boumpasd@med.uoc.gr
Current Rheumatology Reports
|December 21, 2000
Summary
Advances in vasculitis management include optimized antineutrophil cytoplasmic antibody testing and new biologic therapies. Treatment strategies are evolving for various vasculitic syndromes, focusing on efficacy and reduced toxicity.
Area of Science:
- Rheumatology
- Immunology
- Internal Medicine
Background:
- Vasculitic syndromes encompass a group of rare diseases characterized by inflammation of blood vessels.
- Understanding the pathogenesis and natural history of vasculitis is crucial for developing effective treatments.
Purpose of the Study:
- To summarize recent advancements in the management of vasculitic syndromes.
- To discuss emerging therapies informed by a deeper understanding of vasculitis.
- To highlight the impact of improved diagnostic criteria and antibody testing on future treatment.
Main Methods:
- Review of current literature on vasculitis management.
- Discussion of established and investigational therapeutic agents.
- Analysis of diagnostic improvements, including antineutrophil cytoplasmic antibody testing.
Main Results:
- Biologic agents like interferon-alpha are used, with others (e.g., tumor necrosis factor-alpha inhibitors) in clinical trials.
- Novel agents targeting specific pathogenic pathways are in early development.
- Established immunosuppressants (methotrexate, azathioprine) and newer agents (mycophenolate mofetil, leflunamide) are finding expanded roles.
Conclusions:
- Optimized diagnostic strategies and novel biologic agents represent significant progress in vasculitis management.
- Treatment approaches are becoming more tailored, with options for severe cases (cyclophosphamide plus biologics) and less severe forms (immunosuppressants alone).
- Future research should prioritize assessing treatment impact on quality of life and long-term toxicity.